Anti-Cx43 Antibody Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stabilizing antibodies, particularly anti-Cx43 antibodies, face challenges such as denaturation, aggregation, and contamination during storage and transport, with no universal formulation suitable for all antibodies, leading to instability and inefficiencies in administration.
Innovation Solution
A stable aqueous pharmaceutical formulation comprising an anti-Cx43 antibody or antigen binding fragment, a buffer (like histidine/histidine hydrochloride), a surfactant (Polysorbate 80), and a stabilizer (sucrose) at a pH of 5.4 to 5.6, which maintains stability and effectiveness over extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If antibodies are stored in aqueous formulations, then ease of operation is improved, but stability deteriorates due to denaturation, aggregation, and particle formation
Solution Approach 1:
The patent applies parameter changes by optimizing the pH of the aqueous formulation to a specific range (pH 5.0-6.5, preferably pH 5.2-5.8) and controlling antibody concentration (10-100 mg/mL). These parameter adjustments prevent denaturation and aggregation while maintaining the antibody in a stable aqueous state, eliminating the need for lyophilization and enabling direct administration.
Solution Approach 2:
The patent employs composite materials by formulating a complex aqueous solution containing multiple components: anti-Cx43 antibodies, buffers (e.g., histidine, acetate, citrate), surfactants (e.g., polysorbate 80, poloxamer 188), and stabilizers (e.g., sucrose, trehalose, glycine). This composite formulation synergistically prevents denaturation, aggregation, and particle formation while maintaining antibody stability and solubility in aqueous medium.
2Stability of the object's composition
If lyophilization is used to stabilize antibodies, then stability is improved, but device complexity increases due to additional reconstitution steps
Solution Approach 1:
The patent extracts the water removal step (lyophilization) from the formulation process by developing stable aqueous formulations that do not require freeze-drying. The antibody is stabilized in its native aqueous state through optimized pH, buffers, and stabilizers, eliminating the need for reconstitution and simplifying the administration process to a single injectable step.
Solution Approach 2:
The patent applies preliminary action by pre-optimizing the formulation conditions (pH 5.0-6.5, specific buffer systems, surfactant concentrations) before administration. This preliminary optimization ensures stability is achieved in advance, eliminating the need for subsequent reconstitution steps and allowing direct injection of the aqueous formulation.
3Adaptability or versatility
If universal formulations are used for all antibodies, then adaptability is improved, but manufacturing precision deteriorates due to antibody-specific optimization needs
Solution Approach 1:
The patent applies universality by developing a platform formulation system with core components (buffers like histidine/acetate/citrate, surfactants like polysorbate 80/poloxamer 188, stabilizers like sucrose/trehalose/glycine) that can be adapted to stabilize various antibodies. The universal pH range (5.0-6.5) and component classes provide a versatile framework that maintains manufacturing precision through systematic optimization rather than ad-hoc adjustments for each antibody.
Data Source
AI summary
The present disclosure relates to pharmaceutical compositions and methods for treating a disease or condition associated with opening of Cx43 hemichannels in astrocytes or osteocytes, preferably for treating an inflammatory disease or condition or a neurodegenerative disease such as spinal cord injury.